Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone hydrochloride liposome plus duvelisib for relapsed/refractory PTCL and NK/T-cell lymphoma
ChiCTR2300074621Phase 4Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Aug 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of mitoxantrone and duvelisib in peripheral T-cell lymphoma (PTCL), Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) and lymphoma (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoints: Dose-limiting toxicities, Objective response rate and 1 more. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
mitoxantroneduvelisib
03
Conditions
peripheral T-cell lymphoma (PTCL)Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)lymphoma
Beyond the preview
Go deeper on ChiCTR2300074621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074621.